Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Identifieur interne : 000390 ( France/Analysis ); précédent : 000389; suivant : 000391Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Auteurs : Shannon Allen Ferrante [États-Unis] ; Jagpreet Chhatwal [États-Unis] ; Clifford Brass [États-Unis] ; Antoine El Khoury [États-Unis] ; Fred Poordad [États-Unis] ; Jean-Pierre Bronowicki [France] ; Elamin Elbasha [États-Unis]Source :
- BMC Infectious Diseases [ 1471-2334 ] ; 2013-04-27.
English descriptors
Abstract
BACKGROUND: SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV)- nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with chronic HCV genotype 1. We estimated the long-term impact of triple therapy vs. dual therapy on the clinical burden of HCV and performed a cost-effectiveness evaluation. METHODS: A Markov model was used to estimate the incidence of liver complications, discounted costs (2010 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) of three treatment strategies for treatment-naive patients with chronic HCV genotype 1. The model simulates the treatment regimens studied in SPRINT-2 in which PR was administered for 4 weeks followed by: 1) placebo plus PR for 44 weeks (PR48); 2) BOC plus PR using response guided therapy (BOC/RGT); and 3) BOC plus PR for 44 weeks (BOC/PR48) and makes projections within and beyond the trial. HCV-related state-transition probabilities, costs, and utilities were obtained from previously published studies. All costs and QALYs were discounted at 3%. RESULTS: The model projected approximately 38% and 43% relative reductions in the lifetime incidence of liver complications in the BOC/RGT and BOC/PR48 regimens compared with PR48; respectively. Treatment with BOC/RGT is associated with an incremental cost of $10,348 and an increase of 0.62 QALYs compared to treatment with PR48. Treatment with BOC/PR48 is associated with an incremental cost of $35,727 and an increase of 0.65 QALYs compared to treatment with PR48. The ICERs were $16,792/QALY and $55,162/QALY for the boceprevir-based treatment groups compared with PR48, respectively. The ICER for BOC/PR48 compared with BOC/RGT was $807,804. CONCLUSION: The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. Both boceprevir-based treatment strategies were projected to be cost-effective at a reasonable threshold in the US when compared to treatment with PR48.
Url:
DOI: 10.1186/1471-2334-13-190
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000110
- to stream Hal, to step Curation: 000110
- to stream Hal, to step Checkpoint: 000300
- to stream Main, to step Merge: 005D87
- to stream Main, to step Curation: 005A49
- to stream Main, to step Exploration: 005A49
- to stream France, to step Extraction: 000390
Links to Exploration step
Hal:inserm-00820362Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.</title>
<author><name sortKey="Ferrante, Shannon Allen" sort="Ferrante, Shannon Allen" uniqKey="Ferrante S" first="Shannon Allen" last="Ferrante">Shannon Allen Ferrante</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chhatwal, Jagpreet" sort="Chhatwal, Jagpreet" uniqKey="Chhatwal J" first="Jagpreet" last="Chhatwal">Jagpreet Chhatwal</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221126" status="INCOMING"><orgName>Department of Health Policy and Management</orgName>
<desc><address><addrLine>130 De Soto St, Pittsburgh, PA 15213</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-346810" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-346810" type="direct"><org type="institution" xml:id="struct-346810" status="INCOMING"><orgName>University of Pittsburgh Graduate School of Public Health</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brass, Clifford" sort="Brass, Clifford" uniqKey="Brass C" first="Clifford" last="Brass">Clifford Brass</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="El Khoury, Antoine" sort="El Khoury, Antoine" uniqKey="El Khoury A" first="Antoine" last="El Khoury">Antoine El Khoury</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poordad, Fred" sort="Poordad, Fred" uniqKey="Poordad F" first="Fred" last="Poordad">Fred Poordad</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221131" status="INCOMING"><orgName>Hepatology and Liver Transplantation</orgName>
<desc><address><addrLine>8700 Beverly Blvd, West Hollywood, CA 90048</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-324147" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-324147" type="direct"><org type="institution" xml:id="struct-324147" status="VALID"><orgName>Cedars-Sinai Medical Center</orgName>
<desc><address><addrLine>8700 Beverly Blvd, Los Angeles, California 90048</addrLine>
<country key="US"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-409232" status="VALID"><idno type="IdRef">172251281</idno>
<idno type="RNSR">200919208U</idno>
<idno type="IdUnivLorraine">[UL]RNJ--</idno>
<orgName>Nutrition-Génétique et Exposition aux Risques Environnementaux</orgName>
<orgName type="acronym">NGERE</orgName>
<date type="start">2012-01-01</date>
<desc><address><addrLine>Université de Lorraine, Faculté de Médecine, 9 avenue de la Forêt de Haye, 54500 Vandoeuvre-les-Nancy</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation><relation name="UMRS954" active="#struct-303623" type="direct"></relation>
<relation active="#struct-413289" type="direct"></relation>
</listRelation>
<tutelles><tutelle name="UMRS954" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-413289" type="direct"><org type="institution" xml:id="struct-413289" status="VALID"> <idno type="IdUnivLorraine">[UL]100--</idno>
<idno type="IdRef">157040569</idno>
<orgName>Université de Lorraine</orgName>
<orgName type="acronym">UL</orgName>
<date type="start">2012-01-01</date>
<desc> <address> <addrLine>34 cours Léopold - CS 25233 - 54052 Nancy cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.univ-lorraine.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Nancy</settlement>
<settlement type="city">Metz</settlement>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
</placeName>
<orgName type="university">Université de Lorraine</orgName>
</affiliation>
</author>
<author><name sortKey="Elbasha, Elamin" sort="Elbasha, Elamin" uniqKey="Elbasha E" first="Elamin" last="Elbasha">Elamin Elbasha</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:inserm-00820362</idno>
<idno type="halId">inserm-00820362</idno>
<idno type="halUri">http://www.hal.inserm.fr/inserm-00820362</idno>
<idno type="url">http://www.hal.inserm.fr/inserm-00820362</idno>
<idno type="doi">10.1186/1471-2334-13-190</idno>
<date when="2013-04-27">2013-04-27</date>
<idno type="wicri:Area/Hal/Corpus">000110</idno>
<idno type="wicri:Area/Hal/Curation">000110</idno>
<idno type="wicri:Area/Hal/Checkpoint">000300</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000300</idno>
<idno type="wicri:doubleKey">1471-2334:2013:Ferrante S:boceprevir:for:previously</idno>
<idno type="wicri:Area/Main/Merge">005D87</idno>
<idno type="wicri:Area/Main/Curation">005A49</idno>
<idno type="wicri:Area/Main/Exploration">005A49</idno>
<idno type="wicri:Area/France/Extraction">000390</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.</title>
<author><name sortKey="Ferrante, Shannon Allen" sort="Ferrante, Shannon Allen" uniqKey="Ferrante S" first="Shannon Allen" last="Ferrante">Shannon Allen Ferrante</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chhatwal, Jagpreet" sort="Chhatwal, Jagpreet" uniqKey="Chhatwal J" first="Jagpreet" last="Chhatwal">Jagpreet Chhatwal</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221126" status="INCOMING"><orgName>Department of Health Policy and Management</orgName>
<desc><address><addrLine>130 De Soto St, Pittsburgh, PA 15213</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-346810" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-346810" type="direct"><org type="institution" xml:id="struct-346810" status="INCOMING"><orgName>University of Pittsburgh Graduate School of Public Health</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brass, Clifford" sort="Brass, Clifford" uniqKey="Brass C" first="Clifford" last="Brass">Clifford Brass</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="El Khoury, Antoine" sort="El Khoury, Antoine" uniqKey="El Khoury A" first="Antoine" last="El Khoury">Antoine El Khoury</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poordad, Fred" sort="Poordad, Fred" uniqKey="Poordad F" first="Fred" last="Poordad">Fred Poordad</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221131" status="INCOMING"><orgName>Hepatology and Liver Transplantation</orgName>
<desc><address><addrLine>8700 Beverly Blvd, West Hollywood, CA 90048</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-324147" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-324147" type="direct"><org type="institution" xml:id="struct-324147" status="VALID"><orgName>Cedars-Sinai Medical Center</orgName>
<desc><address><addrLine>8700 Beverly Blvd, Los Angeles, California 90048</addrLine>
<country key="US"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-409232" status="VALID"><idno type="IdRef">172251281</idno>
<idno type="RNSR">200919208U</idno>
<idno type="IdUnivLorraine">[UL]RNJ--</idno>
<orgName>Nutrition-Génétique et Exposition aux Risques Environnementaux</orgName>
<orgName type="acronym">NGERE</orgName>
<date type="start">2012-01-01</date>
<desc><address><addrLine>Université de Lorraine, Faculté de Médecine, 9 avenue de la Forêt de Haye, 54500 Vandoeuvre-les-Nancy</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation><relation name="UMRS954" active="#struct-303623" type="direct"></relation>
<relation active="#struct-413289" type="direct"></relation>
</listRelation>
<tutelles><tutelle name="UMRS954" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-413289" type="direct"><org type="institution" xml:id="struct-413289" status="VALID"> <idno type="IdUnivLorraine">[UL]100--</idno>
<idno type="IdRef">157040569</idno>
<orgName>Université de Lorraine</orgName>
<orgName type="acronym">UL</orgName>
<date type="start">2012-01-01</date>
<desc> <address> <addrLine>34 cours Léopold - CS 25233 - 54052 Nancy cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.univ-lorraine.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Nancy</settlement>
<settlement type="city">Metz</settlement>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
</placeName>
<orgName type="university">Université de Lorraine</orgName>
</affiliation>
</author>
<author><name sortKey="Elbasha, Elamin" sort="Elbasha, Elamin" uniqKey="Elbasha E" first="Elamin" last="Elbasha">Elamin Elbasha</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-221125" status="INCOMING"><orgName>Merck Sharp & Dohme Corp.</orgName>
<orgName type="acronym">MSD</orgName>
<desc><address><addrLine>1 Merck Dr, NJ 08889</addrLine>
<country key="US"></country>
</address>
</desc>
<listRelation><relation active="#struct-353781" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-353781" type="direct"><org type="institution" xml:id="struct-353781" status="INCOMING"><orgName>Whitehouse Station</orgName>
<desc><address><country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1186/1471-2334-13-190</idno>
<series><title level="j">BMC Infectious Diseases</title>
<idno type="ISSN">1471-2334</idno>
<imprint><date type="datePub">2013-04-27</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Boceprevir</term>
<term>Cost-effectiveness</term>
<term>Economic evaluation</term>
<term>Hepatitis c virus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND: SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV)- nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with chronic HCV genotype 1. We estimated the long-term impact of triple therapy vs. dual therapy on the clinical burden of HCV and performed a cost-effectiveness evaluation. METHODS: A Markov model was used to estimate the incidence of liver complications, discounted costs (2010 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) of three treatment strategies for treatment-naive patients with chronic HCV genotype 1. The model simulates the treatment regimens studied in SPRINT-2 in which PR was administered for 4 weeks followed by: 1) placebo plus PR for 44 weeks (PR48); 2) BOC plus PR using response guided therapy (BOC/RGT); and 3) BOC plus PR for 44 weeks (BOC/PR48) and makes projections within and beyond the trial. HCV-related state-transition probabilities, costs, and utilities were obtained from previously published studies. All costs and QALYs were discounted at 3%. RESULTS: The model projected approximately 38% and 43% relative reductions in the lifetime incidence of liver complications in the BOC/RGT and BOC/PR48 regimens compared with PR48; respectively. Treatment with BOC/RGT is associated with an incremental cost of $10,348 and an increase of 0.62 QALYs compared to treatment with PR48. Treatment with BOC/PR48 is associated with an incremental cost of $35,727 and an increase of 0.65 QALYs compared to treatment with PR48. The ICERs were $16,792/QALY and $55,162/QALY for the boceprevir-based treatment groups compared with PR48, respectively. The ICER for BOC/PR48 compared with BOC/RGT was $807,804. CONCLUSION: The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. Both boceprevir-based treatment strategies were projected to be cost-effective at a reasonable threshold in the US when compared to treatment with PR48.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Grand Est</li>
<li>Lorraine (région)</li>
</region>
<settlement><li>Metz</li>
<li>Nancy</li>
</settlement>
<orgName><li>Université de Lorraine</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Ferrante, Shannon Allen" sort="Ferrante, Shannon Allen" uniqKey="Ferrante S" first="Shannon Allen" last="Ferrante">Shannon Allen Ferrante</name>
</noRegion>
<name sortKey="Brass, Clifford" sort="Brass, Clifford" uniqKey="Brass C" first="Clifford" last="Brass">Clifford Brass</name>
<name sortKey="Chhatwal, Jagpreet" sort="Chhatwal, Jagpreet" uniqKey="Chhatwal J" first="Jagpreet" last="Chhatwal">Jagpreet Chhatwal</name>
<name sortKey="El Khoury, Antoine" sort="El Khoury, Antoine" uniqKey="El Khoury A" first="Antoine" last="El Khoury">Antoine El Khoury</name>
<name sortKey="Elbasha, Elamin" sort="Elbasha, Elamin" uniqKey="Elbasha E" first="Elamin" last="Elbasha">Elamin Elbasha</name>
<name sortKey="Poordad, Fred" sort="Poordad, Fred" uniqKey="Poordad F" first="Fred" last="Poordad">Fred Poordad</name>
</country>
<country name="France"><region name="Grand Est"><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000390 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000390 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Amérique |area= PittsburghV1 |flux= France |étape= Analysis |type= RBID |clé= Hal:inserm-00820362 |texte= Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. }}
This area was generated with Dilib version V0.6.38. |